Aptevo Therapeutics Reports 2023 Financial Results and Provides a Business Update
Announces 1H24 Plan for Development of Lead Candidate APVO436 for the Treatment of Frontline Acute Myeloid Leukemia, Interim Results Expected...
Coronavirus
MAX BioPharma and Metaba Announce Collaboration on Metabolomics Studies
LOS ANGELES, Feb. 26, 2024 /PRNewswire/ -- Today MAX BioPharma, Inc. (www.maxbiopharma.com) and Metaba, LLC (www.metaba.us) announced their collaboration in...
Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical...
Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024
Event to feature KOL perspective on emerging MASH therapiesSOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics,...
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic
BOSTON, Feb. 20, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively...
Sunshine Biopharma, Inc. Announces Closing of $10.0 Million Underwritten Public Offering
NEW YORK, NY / ACCESSWIRE / February 15, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering...
NanoViricides Has Filed its Quarterly Report – NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon
SHELTON, CT / ACCESSWIRE / February 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in broad-spectrum...
Sunshine Biopharma, Inc. Announces Pricing of $10.0 Million Underwritten Public Offering
NEW YORK, NY / ACCESSWIRE / February 13, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering...
Aligos Therapeutics Strengthens Finance Leadership Team with Two New Appointments
Jordyn Tarazi joins as Vice President, Investor Relations and Corporate Communications Nikhil Aneja, CPA, CA appointed as Vice President, Finance...
Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides – NV-387 Could be As Revolutionary as Antibiotics
SHELTON, CT / ACCESSWIRE / February 1, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development...
Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset
Takeda Will Be Protagonist's Co-Development, U.S. Co-Commercialization Partner With 50:50 Profit Share, and With Exclusive Ex-U.S. Global Rights to Commercialize...
Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found
SHELTON, CT / ACCESSWIRE / January 29, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development...
CVRx Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
MINNEAPOLIS, Jan. 25, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and...
Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
- 10,000-subject Phase 2b study would evaluate Vaxart’s next generation oral pill XBB COVID-19 vaccine against an approved mRNA vaccine...
Emergex Announces R&D Collaboration with DEKA Research & Development Corp. for Assessment of Emergex’s Immunotherapeutic Candidates with DEKA’s Intradermal Therapeutic Applicator
The DEKA Intradermal Therapeutic Applicator The DEKA Intradermal Therapeutic Applicator Emergex has entered into an agreement with DEKA Research &...
CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2023 Financial Results and Announces Nadim Yared Retirement Plans
Fourth quarter revenue expected to be $11.2 million to $11.3 million, representing growth of 56% to 58%Full year revenue expected...
STRATA Skin Sciences to Present Poster Showcasing Safety and Efficacy of TheraClear®X for Acne at Maui Derm 2024 Conference
HORSHAM, Pa., Jan. 08, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology...
NanoViricides to Present at the Biotech Showcase in San Fransisco
SHELTON, CT / ACCESSWIRE / January 4, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development...
TransCode Therapeutics Publishes Open Letter Outlining Company’s Progress and Objectives
Despite Difficult Financial Markets, TransCode Raised New Capital and Initiated Its First Clinical Trial With Its Lead Therapeutic Candidate, A...
Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates
BOTHELL, Wash., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) provides an update...